Stevanato Group Spa (STVN)
NYSE:STVN
Want to see STVN full AI Analyst Report?
Top Page
Stevanato Group
(NYSE:STVN)
Select Model
Select Model
Rating:65Neutral
Price Target:
$19.50
▲(25.56% Upside)
Action:Reiterated
Date:05/10/26
The score is driven by strong growth and constructive guidance, supported by positive technical momentum. It is held back by weak/volatile free cash flow and a relatively full valuation, with additional near-term risks from Engineering softness and FX/tariff/depreciation headwinds.
Positive Factors
Higher mix of high-value solutions
A rising share of high-value solutions (47% of revenue) shifts the business toward higher-margin, program-based supply relationships. This increases recurring, sticky revenue and reduces exposure to commoditized containers, supporting durable margin resilience as capacity utilization improves.
Negative Factors
Free cash flow volatility and slight negative FCF
Volatile and slightly negative free cash flow amid heavy growth capex reduces internal funding capacity and increases reliance on external financing. Over 2–6 months this can constrain strategic flexibility and magnify funding risk if capex remains elevated or demand softens.
Read all positive and negative factors
Positive Factors
Negative Factors
Higher mix of high-value solutions
A rising share of high-value solutions (47% of revenue) shifts the business toward higher-margin, program-based supply relationships. This increases recurring, sticky revenue and reduces exposure to commoditized containers, supporting durable margin resilience as capacity utilization improves.
Read all positive factors
Stevanato Group (STVN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$4.92B
Dividend Yield0.29%
Average Volume (3M)567.47K
Price to Earnings (P/E)29.0
Beta (1Y)0.84
Revenue Growth15.54%
EPS Growth21.77%
CountryUS
Employees5,521
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)0.51
Shares Outstanding49,709,717
10 Day Avg. Volume366,137
30 Day Avg. Volume567,469
Financial Highlights & Ratios
PEG Ratio2.49
Price to Book (P/B)3.15
Price to Sales (P/S)4.10
P/FCF Ratio218.04
Enterprise Value/Market Cap0.93
Enterprise Value/Revenue3.81
Enterprise Value/Gross Profit13.14
Enterprise Value/Ebitda15.75
Forecast
1Y Price Target
$26.07Price Target Upside67.87% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)0.61
Revenue Forecast (FY)$1.28B
Stevanato Group Business Overview & Revenue Model
Company Description
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for pharma and healthcare. Its principal products include containment solutions, drug delivery systems, medical de...
How the Company Makes Money
Stevanato Group primarily makes money by selling products and services used to package, contain, and deliver injectable drugs and to support customers’ manufacturing and device-development needs. Key revenue streams include: (1) High-value drug co...
Stevanato Group Earnings Call Summary
Earnings Call Date:May 07, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 11, 2026
Earnings Call Sentiment Positive
The call highlighted strong top-line growth, robust Biopharmaceutical & Diagnostic Solutions momentum (notably syringes, biologics and GLP1 exposure), expanding high-value solution mix, margin expansion on an adjusted basis, and clear progress on strategic capacity investments. Offsetting these positives were a sharp revenue decline in the Engineering segment, segment-level gross margin compression for BDS driven by ramp-related depreciation, FX and tariff headwinds, a higher tax rate, modest free cash flow in the quarter due to heavy growth capex, and slower order conversion cycles in Engineering. Management reiterated full-year guidance and emphasized demand-driven capacity investment and operational optimization.Positive Updates
Top-line Growth
Revenue grew 10% at constant currency and 7% reported to EUR 273.6 million in Q1 FY2026 versus Q1 2025.
Negative Updates
Engineering Revenue Sharp Decline
Engineering segment revenue declined 31% year-over-year to EUR 24.6 million due to low backlog and slower new order intake, creating timing risk for a recovery in revenue.
Read all updates
Q1-2026 Updates
Positive
Negative
Top-line Growth
Revenue grew 10% at constant currency and 7% reported to EUR 273.6 million in Q1 FY2026 versus Q1 2025.
Read all positive updates
Company Guidance
Stevanato reiterated its 2026 guidance: revenue EUR 1.260–1.290 billion, adjusted EBITDA EUR 331.8–346.9 million, and adjusted diluted EPS EUR 0.59–0.63 (March assumptions unchanged); management expects high‑value solutions to represent ~47–48% of 2026 revenue, GLP‑1 volumes to grow in the mid‑teens year‑over‑year (GLP‑1s are ~21–22% of current revenue), and BDS gross margin to be in line with or slightly above 2025 despite an estimated ~EUR 18 million FX headwind and higher depreciation. They expect roughly 45% of full‑year revenue in H1 with a stronger H2, Q2 BDS growth of high single‑digit to low double‑digit and about a 10% decline in Engineering (Engineering down mid‑single to low‑double digits for the year), and note continued capital investment (Q1 capex EUR 67.6 million, >90% growth‑related) with cash EUR 111.7 million and net debt EUR 337.7 million to fund the plan.Stevanato Group Financial Statement Overview
Summary
Income Statement
76
Positive
Balance Sheet
74
Positive
Cash Flow
45
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.20B | 1.14B | 1.10B | 1.09B | 983.68M | 843.92M |
| Gross Profit | 348.16M | 330.33M | 302.32M | 339.89M | 319.80M | 265.40M |
| EBITDA | 290.46M | 268.18M | 247.80M | 272.35M | 256.40M | 226.93M |
| Net Income | 140.95M | 134.28M | 117.78M | 145.63M | 142.85M | 134.32M |
Balance Sheet | ||||||
| Total Assets | 2.58B | 2.54B | 2.33B | 2.07B | 1.66B | 1.42B |
| Cash, Cash Equivalents and Short-Term Investments | 112.73M | 132.74M | 98.27M | 70.35M | 256.65M | 438.21M |
| Total Debt | 448.52M | 470.70M | 428.97M | 396.59M | 218.37M | 244.29M |
| Total Liabilities | 1.05B | 1.06B | 924.43M | 938.93M | 663.79M | 577.18M |
| Stockholders Equity | 1.53B | 1.49B | 1.40B | 1.13B | 996.13M | 842.07M |
Cash Flow | ||||||
| Free Cash Flow | -7.11M | 21.44M | -157.79M | -336.72M | -139.81M | 20.16M |
| Operating Cash Flow | 260.08M | 274.79M | 155.78M | 105.21M | 103.31M | 133.34M |
| Investing Cash Flow | -271.01M | -262.15M | -310.21M | -421.22M | -242.95M | -96.43M |
| Financing Cash Flow | 32.70M | 21.19M | 183.22M | 158.03M | -44.54M | 254.85M |
Stevanato Group Technical Analysis
Positive
15.53
Price Trends
15.82
Positive
16.54
Positive
20.13
Negative
Market Momentum
0.57
Positive
61.39
Neutral
44.90
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For STVN, the sentiment is Positive. The current price of 15.53 is below the 20-day moving average (MA) of 17.69, below the 50-day MA of 15.82, and below the 200-day MA of 20.13, indicating a neutral trend. The MACD of 0.57 indicates Positive momentum. The RSI at 61.39 is Neutral, neither overbought nor oversold. The STOCH value of 44.90 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for STVN.
Stevanato Group Risk Analysis
Stevanato Group disclosed 64 risk factors in its most recent earnings report. Stevanato Group reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Stevanato Group Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | $2.23B | 39.69 | 16.19% | 0.95% | 13.27% | 36.99% | |
68 Neutral | $3.83B | 25.02 | 8.95% | ― | 11.34% | 12.26% | |
65 Neutral | $4.92B | 28.96 | 9.63% | 0.29% | 15.54% | 21.77% | |
59 Neutral | $6.49B | 199.20 | 2.46% | ― | 17.36% | ― | |
57 Neutral | $5.88B | -162.30 | -28.27% | 1.11% | -6.61% | -812.37% | |
55 Neutral | $7.42B | 27.77 | 14.33% | 1.50% | 8.95% | 6.13% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
STVN
Stevanato Group
18.01
-4.24
-19.05%
ATR
AptarGroup
116.23
-37.50
-24.39%
LMAT
Lemaitre Vascular
97.75
17.09
21.19%
MMSI
Merit Medical Systems
64.17
-31.21
-32.72%
RGEN
Repligen
115.06
-3.09
-2.62%
TFX
Teleflex
132.75
13.34
11.17%
Stevanato Group Corporate Events
Stevanato Group Files Form 6-K Detailing Q1 2026 Results Presentation
May 7, 2026
On May 7, 2026, Stevanato Group S.p.A. furnished a Form 6-K to the U.S. Securities and Exchange Commission as a foreign private issuer, covering its activities for May 2026. The filing lists an investor presentation related to the company’s ...
Stevanato Group Files First-Quarter 2026 Interim Report Highlighting Risk Landscape
May 7, 2026
Stevanato Group has filed an unaudited interim report on Form 6-K for the three months ended March 31, 2026, providing condensed consolidated financial statements and management’s discussion of its financial condition and results. The filing...
Stevanato Group Posts Q1 2026 Revenue Growth and Reaffirms Full-Year Guidance
May 7, 2026
In the first quarter of 2026, Stevanato Group reported revenue of €273.6 million, up 7% year-over-year, or 10% at constant currency, with high-value solutions rising 17% and reaching 47% of total sales. The Biopharmaceutical and Diagnostic S...
Stevanato Group Posts 2025 Growth on High-Value Syringes and GLP‑1 Demand
Mar 12, 2026
On March 4, 2026, Stevanato Group management reviewed fourth-quarter and full-year 2025 results, reporting 2025 revenue growth of 9% at constant currency and 7% on a reported basis versus 2024, driven by double-digit expansion in its Biopharmaceut...
Stevanato Group Posts Record High‑Value Revenue and Strong 2025 Results, Sets Upbeat 2026 Outlook
Mar 4, 2026
On March 4, 2026, Stevanato Group reported that fourth‑quarter 2025 revenue rose 5% year‑on‑year to €346.5 million, with high‑value solutions reaching a record 49% of sales and lifting gross and adjusted EBITDA margin...
Stevanato Group Files Form 6-K With Q4 and FY 2025 Results Presentation
Mar 4, 2026
On March 4, 2026, Stevanato Group filed a Form 6-K with the U.S. Securities and Exchange Commission, furnishing the investor presentation used for its Q4 and full-year 2025 financial results conference call. The filing, signed by CEO Franco Stevan...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.